CMMB Stock — Chemomab Therapeutics Ltd DRC

Chemomab Therapeutics Ltd DRC (CMMB)

Updated October 16, 2026.

CMMB is a Stock. Total return is -99.8% over the past 7.7 years, 311.9 points behind SPY at 212.1%.

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibrotic and inflammatory diseases, with its lead candidate nebokitug—a monoclonal antibody targeting CCL24—currently in phase 2 trials for primary sclerosing cholangitis and systemic sclerosis. The company does not currently distribute income to shareholders. This security appeals to investors focused on biotechnology development and long-term capital appreciation rather than income generation.

CMMB performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.8% over the past 7.7 years, 311.9 points behind SPY at 212.1%. Over the past year its total return — price change plus distributions reinvested — is -61.4%. Its deepest 1-year drawdown was 65.0%.

CMMB key facts

Asset type

Stock

Asset class

Equity

Inception date

02/12/2019

Distribution frequency

None

Last close

$1.26 (as of 2026-10-16)

Market cap

$9,269,490

Average volume

9080.0

Beta

0.763

Payout ratio

0.0%

Forward P/E

12.9366

EPS

$-0.96

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CMMB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 65.0%.

Who may consider CMMB — and who may not

It is a weaker fit for investors who need monthly cash flow (CMMB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CMMB

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions